Xavier Marat
Research Subjects
Xavier Marat has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alice Brule
L'Oréal Research & Innovation Chevilly‐Larue France
1 shared publication - Amélie Prévot‐Guéguiniat
L'Oréal Research and Innovation Aulnay France
1 shared publication - Angelina Roudot
L'Oréal Research & Innovation Chevilly‐Larue France
1 shared publication Annie Black
LANCÔME Levallois‐Peret France
1 shared publication- Audrey Gueniche
L'Oréal Research & Innovation Chevilly‐Larue France
1 shared publication - Carine Tornier
Episkin, Lyon, France
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by Wiley in International Journal of Cosmetic Science
The harnessing potential of carboxymethyl beta glucan: A driver of skin repair
Skin continually faces stresses that compromise its structure and barrier quality, impacting skin appearance and comfort. By sustaining the main biological process of epithelisation, we could improve skin repair, thus correcting skin appearance or discomfort. A stronger barrier will ultimately lead to improvement of the skin surface smoothness, fine lines and radiance. To bolster barrier function, the cohesion of the stratum corneum involving keratinocyte transglutaminase (TGK) and filaggrin (FLG) and the stratum granulosum via tight junction proteins, is critical. Carboxymethyl beta‐glucan (CM‐BG), a water‐soluble derivative of β‐glucan, has shown promise in skin repair and anti‐ageing applications. This study investigates its wound repair potential using in vitro assays and a 3D human full‐thickness wounded skin model. The effects of CM‐BG on various skin biological processes, including inflammation, differentiation and extracellular matrix remodelling, were investigated using a range of in vitro assays. Its potential to promote wound healing, epidermal recovery and barrier function was further assessed in a 3D reconstructed skin model. These comprehensive investigations revealed CM‐BG's multifaceted actions in skin biology. Findings showed CM‐BG selectively activates Dectin‐1 receptors in a concentration‐dependent manner. Furthermore, CM‐BG exhibited anti‐inflammatory properties by inhibiting key pro‐inflammatory mediators (PGE2, IL‐12/IL‐23p40, IL‐1β) while promoting the release of anti‐inflammatory cytokines IL‐10. Additionally, CM‐BG significantly enhanced the expression of TGK, tight junction proteins (Claudin‐1, Zonula occludens‐1 and Occludin) and collagen type I. A 3D skin wound healing model confirmed these findings. CM‐BG accelerated wound repair, reduced Transepidermal Water Loss and increased epidermal/dermal thickness in the wounded area. Additionally, post‐injury, CM‐BG also showed increased expression of key markers on the 3D reconstructed skin model. These results suggest CM‐BG is a valuable topical ingredient for promoting wound healing, skin repair and mitigating skin ageing by interacting with Dectin‐1 receptors, modulating inflammation, improving skin barrier function and boosting collagen production. Further clinical studies are warranted to confirm these promising findings.
- 22 June 2026
- Published by Wiley in International Journal of Cosmetic Science
Open AccessThe harnessing potential of carboxymethyl beta glucan: A driver of skin repair
Skin continually faces stresses that compromise its structure and barrier quality, impacting skin appearance and comfort. By sustaining the main biological process of epithelisation, we could improve skin repair, thus correcting skin appearance or discomfort. A stronger barrier will ultimately lead to improvement of the skin surface smoothness, fine lines and radiance. To bolster barrier function, the cohesion of the stratum corneum involving keratinocyte transglutaminase (TGK) and filaggrin (FLG) and the stratum granulosum via tight junction proteins, is critical. Carboxymethyl beta‐glucan (CM‐BG), a water‐soluble derivative of β‐glucan, has shown promise in skin repair and anti‐ageing applications. This study investigates its wound repair potential using in vitro assays and a 3D human full‐thickness wounded skin model. The effects of CM‐BG on various skin biological processes, including inflammation, differentiation and extracellular matrix remodelling, were investigated using a range of in vitro assays. Its potential to promote wound healing, epidermal recovery and barrier function was further assessed in a 3D reconstructed skin model. These comprehensive investigations revealed CM‐BG's multifaceted actions in skin biology. Findings showed CM‐BG selectively activates Dectin‐1 receptors in a concentration‐dependent manner. Furthermore, CM‐BG exhibited anti‐inflammatory properties by inhibiting key pro‐inflammatory mediators (PGE2, IL‐12/IL‐23p40, IL‐1β) while promoting the release of anti‐inflammatory cytokines IL‐10. Additionally, CM‐BG significantly enhanced the expression of TGK, tight junction proteins (Claudin‐1, Zonula occludens‐1 and Occludin) and collagen type I. A 3D skin wound healing model confirmed these findings. CM‐BG accelerated wound repair, reduced Transepidermal Water Loss and increased epidermal/dermal thickness in the wounded area. Additionally, post‐injury, CM‐BG also showed increased expression of key markers on the 3D reconstructed skin model. These results suggest CM‐BG is a valuable topical ingredient for promoting wound healing, skin repair and mitigating skin ageing by interacting with Dectin‐1 receptors, modulating inflammation, improving skin barrier function and boosting collagen production. Further clinical studies are warranted to confirm these promising findings.
- 19 August 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (3) , 758-770.e7
Exploring the Role of Fibroblast Heterogeneity from Different Skin Types in Epidermal Regeneration In Vitro
- 19 August 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (3) , 758-770.e7
Exploring the Role of Fibroblast Heterogeneity from Different Skin Types in Epidermal Regeneration In Vitro
- Open Access
- 1 April 2024
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 37 (4) , 462-479
2‐Mercaptonicotinoyl glycine, a new potent melanogenesis inhibitor, exhibits a unique mode of action while preserving melanocyte integrity
Research on new ingredients that can prevent excessive melanin production in the skin while considering efficacy, safety but also environmental impact is of great importance to significantly improve the profile of existing actives on the market and avoid undesirable side effects. Here, the discovery of an innovative technology for the management of hyperpigmentation is described. High‐throughput screening tests on a wide chemical diversity of molecules and in silico predictive methodologies were essential to design an original thiopyridinone backbone and select 2‐mercaptonicotinoyl glycine (2‐MNG) as exhibiting the most favorable balance between the impact on water footprint, skin penetration potential and performance. The effectiveness of 2‐MNG was confirmed by topical application on pigmented reconstructed epidermis and human skin explants. In addition, experiments have shown that unlike most melanogenesis inhibitors on the market, this molecule is not a tyrosinase inhibitor. 2‐MNG binds to certain melanin precursors, preventing their integration into growing melanin and leading to inhibition of eumelanin and pheomelanin synthesis, without compromising the integrity of melanocytes.
- 1 April 2024
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 37 (4) , 462-479
Open Access2‐Mercaptonicotinoyl glycine, a new potent melanogenesis inhibitor, exhibits a unique mode of action while preserving melanocyte integrity
Research on new ingredients that can prevent excessive melanin production in the skin while considering efficacy, safety but also environmental impact is of great importance to significantly improve the profile of existing actives on the market and avoid undesirable side effects. Here, the discovery of an innovative technology for the management of hyperpigmentation is described. High‐throughput screening tests on a wide chemical diversity of molecules and in silico predictive methodologies were essential to design an original thiopyridinone backbone and select 2‐mercaptonicotinoyl glycine (2‐MNG) as exhibiting the most favorable balance between the impact on water footprint, skin penetration potential and performance. The effectiveness of 2‐MNG was confirmed by topical application on pigmented reconstructed epidermis and human skin explants. In addition, experiments have shown that unlike most melanogenesis inhibitors on the market, this molecule is not a tyrosinase inhibitor. 2‐MNG binds to certain melanin precursors, preventing their integration into growing melanin and leading to inhibition of eumelanin and pheomelanin synthesis, without compromising the integrity of melanocytes.
- Open Access
- 25 November 2021
- Published by Elsevier in JID Innovations
- Vol. 2 (1) , 100070
Sunscreens with the New MCE Filter Cover the Whole UV Spectrum: Improved UVA1 Photoprotection In Vitro and in a Randomized Controlled Trial
- 25 November 2021
- Published by Elsevier in JID Innovations
- Vol. 2 (1) , 100070
Open AccessSunscreens with the New MCE Filter Cover the Whole UV Spectrum: Improved UVA1 Photoprotection In Vitro and in a Randomized Controlled Trial